To meet the demands of ever shorter cell line construction timelines, especially for the production of complex protein therapeutics such as bispecific antibodies, highly optimized cell technologies and processes are required. This presentation demonstrates how combining the GS piggyBac® transposase technology and the Beacon® Optofluidic System can meet these demands. 

Author: Sarah Turner, Senior Group Leader, R&D

Latest content

Latest briefing from the Knowledge Center